# Production Roadmap: From Demo to Amazing
## Ternary VAE Bioinformatics - Complete Implementation Plan

**Created:** December 29, 2025
**Goal:** Transform 8 demo tools into production-ready, publication-quality implementations

---

## Executive Vision

**Current State:** 8 functional demo tools with mock data and simplified models
**Target State:** Production systems with real data, validated models, and impressive results

### What "Amazing" Means for Each Partner

| Partner | Current Impact | Amazing Impact |
|---------|---------------|----------------|
| **Alejandra Rojas** | Demo primers | Validated diagnostic kit for Paraguay arboviruses |
| **Carlos Brizuela** | Mock peptides | Novel AMPs ready for synthesis and testing |
| **Jose Colbes** | Simulated stability | Predictions validated against experimental data |
| **HIV Package** | Example reports | Clinical decision support integrated with real workflows |

---

## Part 1: Alejandra Rojas - Arbovirus Surveillance

### A2: Pan-Arbovirus Primer Library

#### Current State
- 70 primers generated for 7 viruses
- Random sequences (not real viral genomes)
- Cross-reactivity checking works but on mock data
- P-adic stability scoring functional

#### What's Needed for Production

**1. Real Viral Sequences (Priority: CRITICAL)**

| Virus | NCBI Accession Strategy | Target Sequences |
|-------|------------------------|------------------|
| DENV-1 | Search "Dengue virus 1 complete genome Paraguay" | 50-100 isolates |
| DENV-2 | Focus on 2019-2024 South American outbreaks | 50-100 isolates |
| DENV-3 | Include Caribbean and Central American strains | 30-50 isolates |
| DENV-4 | Fewer isolates, but ensure coverage | 20-30 isolates |
| ZIKV | Post-2015 American lineage | 50-100 isolates |
| CHIKV | Asian and ECSA lineages in Americas | 30-50 isolates |
| MAYV | Limited sequences, get all available | All available |

**Implementation:**
```
Data Source: NCBI Virus (https://www.ncbi.nlm.nih.gov/labs/virus/)
API: Entrez E-utilities
Format: FASTA + GenBank metadata
Storage: Local SQLite database with alignment cache
```

**2. Multiple Sequence Alignment Pipeline**

| Step | Tool | Purpose |
|------|------|---------|
| Download | Entrez API | Fetch sequences by taxonomy |
| Filter | Custom | Remove partial, low-quality |
| Align | MAFFT/Clustal Omega | Generate MSA per virus |
| Conserve | Custom | Identify conserved regions |
| Design | A2 script | Generate primers from conserved |

**3. Enhanced Cross-Reactivity**

| Feature | Current | Production |
|---------|---------|------------|
| Homology check | 70% threshold | BLAST against all targets |
| Specificity | Binary yes/no | Quantitative Tm differential |
| Validation | None | In-silico PCR simulation |

**4. Primer Validation Pipeline**

| Validation Type | Tool/Method |
|-----------------|-------------|
| In-silico PCR | Primer3 + isPCR |
| Secondary structure | mFold/UNAfold |
| Dimer prediction | OligoAnalyzer API |
| Tm validation | Nearest-neighbor thermodynamics |

**5. Output Enhancements**

- Multiplexed panel recommendations (which primers work together)
- Probe sequences for qPCR (TaqMan-style)
- Ordering format for Thermo/IDT/Sigma
- Validation protocol document

#### Deliverables for Amazing A2

| Deliverable | Description | Impact |
|-------------|-------------|--------|
| **Validated Primer Set** | 3-5 primers per virus, experimentally validated | Ready for diagnostic use |
| **Multiplex Panel** | Single reaction detecting all 7 viruses | Publication-worthy |
| **Stability Report** | P-adic analysis showing evolutionary robustness | Novel methodology |
| **Laboratory Protocol** | Complete SOP for RT-PCR | Immediately usable |

---

## Part 2: Carlos Brizuela - Antimicrobial Peptides

### B1: Pathogen-Specific AMP Design

#### Current State
- NSGA-II optimization working
- Mock activity predictors (energy-based proxies)
- 15 Pareto-optimal candidates generated
- No real VAE latent space connection

#### What's Needed for Production

**1. Real VAE Integration (Priority: CRITICAL)**

```python
# Current (mock):
def decode_latent(z):
    return random_sequence()

# Production:
from src.models import TernaryVAEV5_11_PartialFreeze

class RealVAEDecoder:
    def __init__(self, checkpoint="homeostatic_rich/best.pt"):
        self.vae = TernaryVAEV5_11_PartialFreeze(...)
        self.vae.load_state_dict(torch.load(checkpoint))

    def decode(self, z):
        # Decode latent → ternary ops → codons → amino acids
        return self.vae.decode(z)
```

**2. Trained Activity Predictors**

| Pathogen | Training Data Source | Model Type |
|----------|---------------------|------------|
| *A. baumannii* | DRAMP + APD3 databases | Gradient Boosting |
| *P. aeruginosa* | CAMP + DRAMP | Random Forest |
| *K. pneumoniae* | Literature MIC values | Neural Network |
| *S. aureus* | DBAASP database | Ensemble |

**Training Pipeline:**
```
1. Download: DRAMP (http://dramp.cpu-bioinfor.org/)
2. Filter: Gram-negative active peptides
3. Features: AAC, DPC, CTD, PseAAC
4. Train: 5-fold CV, hyperparameter optimization
5. Validate: Hold-out test set (10%)
```

**3. Toxicity Predictor**

| Model | Training Data | Metrics |
|-------|--------------|---------|
| Hemolysis | HemoPI database | IC50 prediction |
| Cytotoxicity | CellPPD | EC50 prediction |
| Selectivity | Combined | Therapeutic index |

**4. Structure Prediction**

| Step | Tool | Purpose |
|------|------|---------|
| Secondary | PSIPRED/JPred | Alpha-helix propensity |
| 3D model | ESMFold/AlphaFold2 | Full structure |
| Membrane | OPM/PPM | Membrane orientation |

#### Deliverables for Amazing B1

| Deliverable | Description | Impact |
|-------------|-------------|--------|
| **Top 10 Validated Peptides** | Predicted MIC < 8 μg/mL, SI > 10 | Synthesis-ready |
| **Activity Predictor Models** | Trained on >10,000 peptides | Reusable tool |
| **Structure Gallery** | ESMFold structures for all candidates | Publication figures |
| **Mechanism Analysis** | Membrane disruption mode prediction | Mechanistic insight |

---

### B8: Microbiome-Safe AMPs

#### Current State
- Selectivity Index (SI) calculation working
- Mock MIC predictions for pathogens and commensals
- SI of 1.26 achieved (want > 4.0)

#### What's Needed for Production

**1. Species-Specific MIC Models**

| Category | Species | Data Source |
|----------|---------|-------------|
| **Pathogens** | *S. aureus*, MRSA, *P. acnes* | DRAMP, literature |
| **Commensals** | *S. epidermidis*, *C. acnes*, *Corynebacterium* | Limited data - need proxies |

**Challenge:** Commensal MIC data is rare. Solutions:
- Use membrane composition similarity to model
- Transfer learning from related pathogens
- Conservative estimates (higher MIC = safer)

**2. Microbiome Context**

| Application | Additional Organisms | Rationale |
|-------------|---------------------|-----------|
| **Skin** | *Malassezia*, *Propionibacterium* | Fungal/bacterial balance |
| **Gut** | *Lactobacillus*, *Bifidobacterium*, *Bacteroides* | Oral AMPs |
| **Respiratory** | *Streptococcus*, *Haemophilus* | Inhalation |

**3. Selectivity Optimization Targets**

| Current SI | Target SI | Strategy |
|------------|-----------|----------|
| 1.26 | 2.0 | Adjust objective weights |
| 2.0 | 4.0 | Add more commensal constraints |
| 4.0+ | 10.0 | Multi-round optimization |

#### Deliverables for Amazing B8

| Deliverable | Description | Impact |
|-------------|-------------|--------|
| **SI > 4.0 Peptides** | Truly selective candidates | Clinical relevance |
| **Microbiome Impact Score** | Comprehensive selectivity metric | Novel contribution |
| **Application-Specific Sets** | Skin, gut, respiratory panels | Therapeutic focus |

---

### B10: Synthesis Optimization

#### Current State
- Synthesis difficulty scoring working
- Cost estimation ($36-37/mg)
- Coupling efficiency ~50%

#### What's Needed for Production

**1. Validated Difficulty Model**

| Factor | Current Model | Production Model |
|--------|---------------|------------------|
| Aggregation | Sequence-based rules | ML on synthesis failure data |
| Coupling | Literature values | Vendor success rate data |
| Racemization | Position-based | Condition-specific model |

**2. Vendor Integration**

| Vendor | API/Data | Purpose |
|--------|----------|---------|
| GenScript | Quote API | Real-time pricing |
| Thermo | Catalog data | Standard peptide costs |
| LifeTein | Success rate database | Difficulty validation |

**3. Scale-Up Planning**

| Scale | mg | Cost Model | Considerations |
|-------|-----|-----------|----------------|
| Research | 5-25 | Per-amino-acid | Purity focus |
| Pre-clinical | 100-500 | Batch economics | GMP-like |
| Clinical | 1-10g | Manufacturing | CMC requirements |

#### Deliverables for Amazing B10

| Deliverable | Description | Impact |
|-------------|-------------|--------|
| **Synthesis Success Predictor** | 85%+ accuracy on vendor data | Practical utility |
| **Cost Optimizer** | Minimize cost while maintaining activity | Budget-conscious |
| **Manufacturing Readiness** | Scale-up recommendations | Translation potential |

---

## Part 3: Jose Colbes - Protein Stability

### C1: Rosetta-Blind Detection

#### Current State
- 23.6% Rosetta-blind residues detected
- Mock Rosetta and geometric scores
- Amino acid enrichment analysis working

#### What's Needed for Production

**1. Real Rosetta Integration**

```python
# Production Rosetta Integration
from pyrosetta import init, pose_from_pdb
from pyrosetta.rosetta.core.scoring import ScoreFunction

init()

def get_real_rosetta_score(pdb_file, residue_number):
    pose = pose_from_pdb(pdb_file)
    sfxn = ScoreFunction()
    sfxn.set_weight(fa_atr, 1.0)  # Attractive
    sfxn.set_weight(fa_rep, 0.55)  # Repulsive
    # ... full ref2015 weights
    return sfxn.score(pose)
```

**2. PDB Structure Database**

| Source | Structures | Purpose |
|--------|-----------|---------|
| PDB | 200,000+ | General proteins |
| AlphaFold DB | 200M+ | Predicted structures |
| PDB-REDO | Optimized | Better geometry |

**3. Validation Dataset**

| Dataset | Mutations | Purpose |
|---------|-----------|---------|
| ProTherm | 25,000+ | Experimental ΔΔG |
| ThermoMutDB | 15,000+ | Additional validation |
| ProteinGym | Benchmarks | Standardized testing |

**4. Enhanced Geometric Scoring**

| Feature | Current | Production |
|---------|---------|------------|
| P-adic valuation | Codon-level | Residue + structure level |
| Hyperbolic distance | Mock | Real coordinate geometry |
| Contact analysis | None | Full contact map |

#### Deliverables for Amazing C1

| Deliverable | Description | Impact |
|-------------|-------------|--------|
| **Rosetta-Blind Database** | Analysis of 1000+ proteins | Resource for field |
| **Discordance Predictor** | ML model for blind spots | Novel tool |
| **Validation Paper** | Correlation with experimental ΔΔG | Publication |

---

### C4: Mutation Effect Predictor

#### Current State
- ΔΔG predictions working (mock coefficients)
- 21 mutations analyzed
- Context-aware (core/surface/interface)

#### What's Needed for Production

**1. Training on Experimental Data**

```python
# ProTherm Training Pipeline
import pandas as pd
from sklearn.ensemble import GradientBoostingRegressor

# Load ProTherm
protherm = pd.read_csv("protherm_database.csv")

# Features
features = [
    'volume_change',
    'hydrophobicity_change',
    'charge_change',
    'geometric_score',
    'entropy_change',
    'secondary_structure',
    'solvent_accessibility',
    'padic_valuation'
]

# Train
model = GradientBoostingRegressor(n_estimators=500)
model.fit(protherm[features], protherm['ddG'])
```

**2. Benchmark Performance**

| Benchmark | Metric | Target |
|-----------|--------|--------|
| ProTherm hold-out | Pearson r | > 0.6 |
| ProteinGym | Spearman ρ | Top 10% |
| S669 | RMSE | < 1.5 kcal/mol |

**3. P-adic Feature Engineering**

| Feature | Description | Hypothesis |
|---------|-------------|------------|
| Valuation change | Δ(p-adic valuation) | Hierarchy disruption |
| Radius change | Δ(hyperbolic radius) | Stability shift |
| Cross-level contacts | Changes across hierarchy | Network effects |

#### Deliverables for Amazing C4

| Deliverable | Description | Impact |
|-------------|-------------|--------|
| **Trained ΔΔG Predictor** | r > 0.6 on ProTherm | Competitive tool |
| **P-adic Feature Contribution** | SHAP analysis | Novel insight |
| **Web Interface** | Single mutation prediction | Usability |

---

## Part 4: HIV Research Package

### H6: TDR Screening

#### Current State
- Complete WHO SDRM list (27 mutations)
- 12 drugs with susceptibility prediction
- Mock sequence analysis

#### What's Needed for Production

**1. Real Sequence Parsing**

```python
# FASTA Parsing + HXB2 Alignment
from Bio import SeqIO, AlignIO
from Bio.Align import PairwiseAligner

def align_to_hxb2(patient_sequence):
    hxb2_pol = load_hxb2_reference()
    aligner = PairwiseAligner()
    alignment = aligner.align(hxb2_pol, patient_sequence)
    return extract_mutations(alignment)
```

**2. Stanford HIVdb Integration**

| Integration | Method | Purpose |
|-------------|--------|---------|
| **API** | REST calls to Sierra | Real-time interpretation |
| **Database** | Local HIVDB copy | Offline capability |
| **Algorithm** | ASI (Algorithm Spec Interface) | Custom scoring |

**API Example:**
```python
import requests

def query_stanford(sequence):
    url = "https://hivdb.stanford.edu/graphql"
    query = """
    mutation {
      sequenceAnalysis(sequences: [{header: "patient", sequence: "%s"}]) {
        drugResistance { drugClass { name } drug { name } score }
      }
    }
    """ % sequence
    return requests.post(url, json={"query": query})
```

**3. Minority Variant Detection**

| Technology | Detection Limit | Application |
|------------|-----------------|-------------|
| Sanger | 20% | Standard genotyping |
| NGS | 1-5% | Transmitted resistance |
| UDS | 0.1% | Research applications |

**4. Subtype-Specific Adjustments**

| Subtype | Prevalence | Specific Mutations |
|---------|------------|-------------------|
| B | Americas/Europe | Standard interpretation |
| C | Africa/India | K65R natural polymorphism |
| CRF01_AE | Asia | E138A baseline |

#### Deliverables for Amazing H6

| Deliverable | Description | Impact |
|-------------|-------------|--------|
| **Stanford-Integrated Reports** | Professional resistance reports | Clinical utility |
| **Minority Variant Mode** | NGS-compatible analysis | Advanced capability |
| **Surveillance Dashboard** | TDR trends visualization | Public health value |

---

### H7: LA Injectable Selection

#### Current State
- Eligibility criteria assessment working
- Success probability calculation
- 40% eligible, 83.5% mean success in demo

#### What's Needed for Production

**1. Clinical Data Integration**

| Data Source | Information | Purpose |
|-------------|-------------|---------|
| EHR | VL history, CD4 trends | Suppression verification |
| Pharmacy | Refill patterns | Adherence estimation |
| Appointments | Visit compliance | Injection reliability |

**2. Enhanced Risk Modeling**

| Risk Factor | Current Weight | Data-Driven Weight |
|-------------|----------------|---------------------|
| Prior NNRTI failure | -15% | Train on outcomes |
| BMI > 30 | -10% | PK modeling |
| Injection concerns | -10% | Anatomical assessment |

**3. Pharmacokinetic Integration**

```python
# PK-based eligibility
def assess_pk_adequacy(patient):
    # CAB-LA trough target: >4x IC90 (0.166 μg/mL target)
    bmi = patient['bmi']
    injection_site = patient['injection_site']

    # Population PK model
    if bmi > 30:
        trough_multiplier = 0.8  # Lower exposure
    else:
        trough_multiplier = 1.0

    if injection_site == 'ventrogluteal':
        trough_multiplier *= 1.1  # Better absorption

    return trough_multiplier > 0.9
```

**4. Outcome Tracking**

| Timepoint | Metric | Target |
|-----------|--------|--------|
| 24 weeks | Viral suppression | > 95% |
| 48 weeks | Viral suppression | > 90% |
| 96 weeks | Viral suppression | > 85% |

#### Deliverables for Amazing H7

| Deliverable | Description | Impact |
|-------------|-------------|--------|
| **Outcome-Validated Model** | Trained on real switch outcomes | Evidence-based |
| **PK Dashboard** | Drug level predictions | Personalized medicine |
| **Patient Decision Aid** | Visual eligibility explanation | Shared decision-making |

---

## Part 5: Cross-Cutting Requirements

### VAE Integration for All Tools

**Central VAE Service:**

```python
# Shared VAE interface for all tools
class TernaryVAEService:
    def __init__(self):
        self.model = TernaryVAEV5_11_PartialFreeze(
            latent_dim=16,
            hidden_dim=64,
            max_radius=0.99,
            use_controller=True
        )
        self.model.load_state_dict(
            torch.load("homeostatic_rich/best.pt")
        )

    def encode(self, sequence):
        """Sequence → latent vector"""
        ops = sequence_to_ternary_ops(sequence)
        return self.model.encode(ops)

    def decode(self, z):
        """Latent vector → sequence"""
        ops = self.model.decode(z)
        return ternary_ops_to_sequence(ops)

    def get_stability(self, z):
        """P-adic stability from latent position"""
        radius = z.norm(dim=-1)
        valuation = radius_to_valuation(radius)
        return valuation
```

### Data Pipeline Architecture

```
┌─────────────────────────────────────────────────────────────┐
│                    DATA SOURCES                              │
├──────────┬──────────┬──────────┬──────────┬────────────────┤
│  NCBI    │  DRAMP   │  PDB     │ Stanford │ Clinical EHR   │
│ Viruses  │  AMPs    │ Proteins │  HIVdb   │ (if available) │
└────┬─────┴────┬─────┴────┬─────┴────┬─────┴───────┬────────┘
     │          │          │          │             │
     ▼          ▼          ▼          ▼             ▼
┌─────────────────────────────────────────────────────────────┐
│                   INGESTION LAYER                            │
│  • API connectors (Entrez, REST)                            │
│  • Data validation and cleaning                              │
│  • Format standardization                                    │
│  • Local caching (SQLite)                                    │
└─────────────────────────────────────────────────────────────┘
     │
     ▼
┌─────────────────────────────────────────────────────────────┐
│                   PROCESSING LAYER                           │
│  • Sequence alignment (MAFFT, BLAST)                        │
│  • Feature extraction                                        │
│  • VAE encoding/decoding                                     │
│  • P-adic valuation calculation                              │
└─────────────────────────────────────────────────────────────┘
     │
     ▼
┌─────────────────────────────────────────────────────────────┐
│                   APPLICATION LAYER                          │
│  ┌──────┐ ┌──────┐ ┌──────┐ ┌──────┐ ┌──────┐ ┌──────┐     │
│  │  A2  │ │  B1  │ │  B8  │ │  B10 │ │  C1  │ │  C4  │     │
│  └──────┘ └──────┘ └──────┘ └──────┘ └──────┘ └──────┘     │
│  ┌──────┐ ┌──────┐                                          │
│  │  H6  │ │  H7  │                                          │
│  └──────┘ └──────┘                                          │
└─────────────────────────────────────────────────────────────┘
     │
     ▼
┌─────────────────────────────────────────────────────────────┐
│                   OUTPUT LAYER                               │
│  • Reports (PDF, HTML)                                       │
│  • Data exports (CSV, JSON, FASTA)                          │
│  • Visualizations (plots, structures)                        │
│  • API endpoints (future)                                    │
└─────────────────────────────────────────────────────────────┘
```

---

## Part 6: Implementation Phases

### Phase 1: Foundation (Week 1-2)

| Task | Tools | Deliverable |
|------|-------|-------------|
| Real VAE integration | All | Shared VAE service |
| Data ingestion framework | All | Modular connectors |
| Configuration management | All | YAML-based configs |
| Logging and monitoring | All | Structured logs |

### Phase 2: Data Integration (Week 3-4)

| Task | Tools | Deliverable |
|------|-------|-------------|
| NCBI arbovirus sequences | A2 | 500+ aligned sequences |
| DRAMP peptide database | B1, B8 | 10,000+ peptides |
| ProTherm stability data | C1, C4 | 25,000+ mutations |
| Stanford HIVdb API | H6, H7 | Live resistance calls |

### Phase 3: Model Training (Week 5-6)

| Task | Tools | Deliverable |
|------|-------|-------------|
| Activity predictors | B1 | 4 pathogen models |
| Selectivity models | B8 | Multi-species MIC |
| ΔΔG predictor | C4 | Trained regressor |
| Rosetta integration | C1 | PyRosetta pipeline |

### Phase 4: Validation (Week 7-8)

| Task | Tools | Deliverable |
|------|-------|-------------|
| Primer in-silico validation | A2 | Specificity confirmed |
| Activity benchmarking | B1 | AUROC > 0.85 |
| ΔΔG benchmarking | C4 | Pearson r > 0.6 |
| Stanford concordance | H6 | > 95% agreement |

### Phase 5: Polish (Week 9-10)

| Task | Tools | Deliverable |
|------|-------|-------------|
| Report generation | All | PDF/HTML reports |
| Visualization | All | Publication figures |
| Documentation | All | User manuals |
| Demo preparation | All | Presentation materials |

---

## Part 7: Resource Requirements

### Compute Resources

| Resource | Specification | Purpose |
|----------|--------------|---------|
| GPU | 1x NVIDIA A100 (40GB) | VAE inference, ESMFold |
| CPU | 16+ cores | Alignment, optimization |
| RAM | 64GB+ | Large datasets |
| Storage | 500GB SSD | Databases, caches |

### Software Dependencies

| Category | Tools |
|----------|-------|
| **Core** | Python 3.11, PyTorch 2.0+, NumPy, Pandas |
| **Bioinformatics** | BioPython, MAFFT, BLAST+ |
| **ML** | scikit-learn, XGBoost, Optuna |
| **Proteins** | PyRosetta, ESMFold, py3Dmol |
| **Visualization** | Matplotlib, Seaborn, Plotly |

### External APIs

| API | Purpose | Cost |
|-----|---------|------|
| NCBI Entrez | Sequence download | Free |
| Stanford HIVdb | Resistance interpretation | Free |
| ESMFold | Structure prediction | Free |
| AlphaFold DB | Pre-computed structures | Free |

---

## Part 8: Success Metrics

### Per-Tool Metrics

| Tool | Metric | Demo Value | Target Value |
|------|--------|------------|--------------|
| **A2** | Specific primers per virus | 0 | 3-5 |
| **A2** | In-silico validation pass | N/A | 100% |
| **B1** | Predicted MIC < 8 μg/mL | Mock | Top 10 validated |
| **B1** | Activity predictor AUROC | N/A | > 0.85 |
| **B8** | Selectivity Index | 1.26 | > 4.0 |
| **B10** | Synthesis success prediction | Mock | > 85% accuracy |
| **C1** | Rosetta-blind rate | 23.6% | Validated experimentally |
| **C4** | ΔΔG Pearson correlation | N/A | > 0.6 |
| **H6** | Stanford concordance | N/A | > 95% |
| **H7** | Outcome prediction accuracy | Mock | > 80% |

### Overall Success

| Milestone | Definition |
|-----------|------------|
| **Functional** | All tools run with real data |
| **Validated** | Benchmarks meet targets |
| **Publication-Ready** | Results support manuscript |
| **Amazing** | Partners present at conferences |

---

## Part 9: Risk Mitigation

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| Limited commensal MIC data | High | B8 selectivity | Use membrane similarity proxies |
| PyRosetta installation issues | Medium | C1 functionality | Pre-compute Rosetta scores |
| NCBI API rate limits | Medium | A2 data access | Bulk download, local cache |
| Stanford API changes | Low | H6 interpretation | Mirror algorithm locally |
| VAE checkpoint corruption | Low | All tools | Multiple backup copies |

---

## Part 10: Deliverables Summary

### For Alejandra Rojas (IICS-UNA)

| Item | Description |
|------|-------------|
| Validated Primer Panel | 21+ primers (3 per virus) with in-silico validation |
| Multiplex Protocol | Single-tube detection of all 7 arboviruses |
| Laboratory SOP | Complete protocol for RT-PCR |
| Manuscript Draft | Methods + results for publication |

### For Carlos Brizuela

| Item | Description |
|------|-------------|
| Top 10 AMP Candidates | Validated activity predictions, synthesis-ready |
| Activity Predictor Suite | 4 pathogen-specific models |
| Microbiome-Safe Panel | SI > 4.0 peptides for skin application |
| Synthesis Roadmap | Cost-optimized candidates for wet-lab |

### For Jose Colbes

| Item | Description |
|------|-------------|
| Rosetta-Blind Analysis | 1000+ proteins analyzed |
| ΔΔG Predictor | Trained model with benchmarks |
| Validation Dataset | Correlation with ProTherm |
| Manuscript Draft | Novel p-adic stability insights |

### For HIV Research Package

| Item | Description |
|------|-------------|
| TDR Screening Tool | Stanford-integrated, clinical-ready |
| LA Eligibility Tool | Risk-stratified recommendations |
| Clinical Protocols | SOPs for both tools |
| Validation Report | Concordance with gold standards |

---

## Conclusion

This roadmap transforms 8 demo tools into production-ready systems that will:

1. **Impress Partners** with validated, working tools
2. **Enable Research** with novel p-adic insights
3. **Support Publications** with benchmarked results
4. **Create Value** through practical clinical/research utility

**Estimated Timeline:** 10 weeks for full production
**Quick Wins:** VAE integration + real data in 2 weeks

---

*Part of the Ternary VAE Bioinformatics Partnership*
*Roadmap for Production Excellence*
